Two prevalent CYP17 mutations and genotype-phenotype correlations in 24 Brazilian patients with 17-hydroxylase deficiency.
We performed molecular genetic analysis of 24 subjects from 19 families with 17-hydroxylase deficiency in Brazil. Of 7 novel CYP17 mutations, 2 (W406R and R362C) account for 50% and 32% of the mutant alleles, respectively. Both mutations were completely inactive when studied in COS-7 cells and yeast microsomes; however, phenotypic features varied among subjects. Some 46,XY individuals with these genotypes had ambiguous genitalia, and other subjects had normal blood pressure and/or serum potassium. We found mutations W406R and R362C principally in families with Spanish and Portuguese ancestry, respectively, suggesting that two independent founder effects contribute to the increased prevalence of 17-hydroxylase deficiency in Brazil. Mutations Y329D and P428L retained a trace of activity, yet the two individuals with these mutations had severe hypertension and hypokalemia. The 46,XX female with mutation Y329D reached Tanner stage 5, whereas the 46,XY subject with mutation P428L remained sexually infantile. The severity of hypertension, hypokalemia, 17-deoxysteroid excess, and sex steroid deficiency varied, even among patients with completely inactive CYP17 protein(s). Spontaneous sexual development occurred only in 46,XX females with partial deficiencies. We conclude that other factors, in addition to CYP17 genotype, contribute to the phenotype of individual patients with 17-hydroxylase deficiency.
Costa-Santos
Marivânia
M
Division of Endocrinology and Metabolism, Department of Medicine, Escola Paulista de Medicina, Federal University of Sao Paulo, Sao Paulo, Brazil 04039-034.
Kater
Claudio E
CE
Auchus
Richard J
RJ
D000293:Adolescent; D000312:Adrenal Hyperplasia, Congenital / Q000150:complications / Q000235:genetics*; D000328:Adult; D000818:Animals; D001938:Brazil; D019556:COS Cells; D002460:Cell Line; D002648:Child; D002522:Chlorocebus aethiops; D004252:DNA Mutational Analysis; D005260:Female; D018703:Founder Effect; D015870:Gene Expression; D005838:Genotype; D012739:Gonadal Steroid Hormones / Q000172:deficiency; D006801:Humans; D006973:Hypertension / Q000235:genetics; D007008:Hypokalemia / Q000235:genetics; D008297:Male; D008958:Models, Molecular; D015394:Molecular Structure; D009154:Mutation; D020125:Mutation, Missense; D010641:Phenotype; D016133:Polymerase Chain Reaction; D011174:Portugal / Q000208:ethnology; D011284:Pregnenolone / Q000378:metabolism; D011627:Puberty; D012441:Saccharomyces cerevisiae / Q000378:metabolism; D013030:Spain / Q000208:ethnology; D013254:Steroid 17-alpha-Hydroxylase / Q000235:genetics*; D014162:Transfection; D014316:Tritium
D012739:Gonadal Steroid Hormones; D014316:Tritium; D011284:Pregnenolone; D013254:Steroid 17-alpha-Hydroxylase